BCL2L1 and hepatocellular carcinoma: BCL2L1 has made significant differences in tumor targeting therapy, as a novel tumor promoter, for hepatocellular carcinoma, lung cancer, gastric cancer, and cervical cancer (Park et al., 2015; Cai et al., 2017).